Novel Agent Lowers Lp(a), Meets All End Points in Phase 2 Novel Agent Lowers Lp(a), Meets All End Points in Phase 2

The highest dose of a novel antisense agent was associated with an 80% reduction in lipoprotein(a) in a new phase 2 trial; and 98% of participants reached the goal of an Lp(a) level under 50 mg/dL.Medscape Medical News

Source: Medscape Medical News Headlines - November 14, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news